Simulations Plus Inc
NASDAQ:SLP

Watchlist Manager
Simulations Plus Inc Logo
Simulations Plus Inc
NASDAQ:SLP
Watchlist
Price: 14.61 USD 0.34% Market Closed
Market Cap: $295.3m

Simulations Plus Inc
Additional Paid In Capital

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Simulations Plus Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Simulations Plus Inc
NASDAQ:SLP
Additional Paid In Capital
$163.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
32%
Veeva Systems Inc
NYSE:VEEV
Additional Paid In Capital
$2.8B
CAGR 3-Years
23%
CAGR 5-Years
24%
CAGR 10-Years
23%
Inspire Medical Systems Inc
NYSE:INSP
Additional Paid In Capital
$927.2m
CAGR 3-Years
4%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Additional Paid In Capital
$894.2m
CAGR 3-Years
8%
CAGR 5-Years
127%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Additional Paid In Capital
$1.2B
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
10%
W
Waystar Holding Corp
NASDAQ:WAY
Additional Paid In Capital
$4B
CAGR 3-Years
21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Simulations Plus Inc
Glance View

Market Cap
295.3m USD
Industry
Health Care

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.

SLP Intrinsic Value
14.39 USD
Overvaluation 2%
Intrinsic Value
Price $14.61

See Also

What is Simulations Plus Inc's Additional Paid In Capital?
Additional Paid In Capital
163.2m USD

Based on the financial report for Feb 28, 2026, Simulations Plus Inc's Additional Paid In Capital amounts to 163.2m USD.

What is Simulations Plus Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
32%

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett